Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Harvard Business School
Merck
AstraZeneca
Moodys

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

LAMPIT Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Lampit patents expire, and when can generic versions of Lampit launch?

Lampit is a drug marketed by Bayer Healthcare and is included in one NDA.

The generic ingredient in LAMPIT is nifurtimox. One supplier is listed for this compound. Additional details are available on the nifurtimox profile page.

Summary for LAMPIT
Drug patent expirations by year for LAMPIT
Drug Prices for LAMPIT

See drug prices for LAMPIT

DrugPatentWatch® Estimated Generic Entry Opportunity Date for LAMPIT
Generic Entry Date for LAMPIT*:
Constraining patent/regulatory exclusivity:
INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LAMPIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Drugs for Neglected DiseasesPhase 2
U.S. Food and Drug Administration (FDA)Phase 2
Institute of Parasitology and Biomedicine Lopez NeyraPhase 2

See all LAMPIT clinical trials

US Patents and Regulatory Information for LAMPIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare LAMPIT nifurtimox TABLET;ORAL 213464-001 Aug 6, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Bayer Healthcare LAMPIT nifurtimox TABLET;ORAL 213464-002 Aug 6, 2020 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Bayer Healthcare LAMPIT nifurtimox TABLET;ORAL 213464-001 Aug 6, 2020 RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Bayer Healthcare LAMPIT nifurtimox TABLET;ORAL 213464-002 Aug 6, 2020 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Harvard Business School
Dow
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.